Zhejiang Jingxin Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Zhejiang Jingxin Pharmaceutical Co Ltd cash flow-to-debt ratio. Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has a Cash Flow-to-Debt Ratio of 0.10x as of September 2025, meaning its operating cash flow of CN¥227.64 Million could theoretically repay 0% of its total liabilities (CN¥2.29 Billion) in one year. Check earnings quality score of Zhejiang Jingxin Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Zhejiang Jingxin Pharmaceutical Co Ltd (2002–2025)
Cash flow-to-debt ratio of Zhejiang Jingxin Pharmaceutical Co Ltd from 2002 to 2025. Historical debt coverage capacity for Zhejiang Jingxin Pharmaceutical Co Ltd across 24 annual periods. Check 002020 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Zhejiang Jingxin Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2002–2025)
Zhejiang Jingxin Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for Zhejiang Jingxin Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 002020 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.35x | CN¥781.35 Million | CN¥2.25 Billion | ▲ +18.3% |
| 2024 | 0.29x | CN¥726.16 Million | CN¥2.48 Billion | ▼ -13.1% |
| 2023 | 0.34x | CN¥824.69 Million | CN¥2.45 Billion | ▼ -13.7% |
| 2022 | 0.39x | CN¥855.78 Million | CN¥2.19 Billion | ▲ +68.9% |
| 2021 | 0.23x | CN¥365.02 Million | CN¥1.58 Billion | ▼ -21.8% |
| 2020 | 0.30x | CN¥513.21 Million | CN¥1.73 Billion | ▲ +5.9% |
| 2019 | 0.28x | CN¥535.30 Million | CN¥1.91 Billion | ▼ -24.2% |
| 2018 | 0.37x | CN¥523.40 Million | CN¥1.42 Billion | ▼ -10.1% |
| 2017 | 0.41x | CN¥385.01 Million | CN¥938.43 Million | ▲ +40.3% |
| 2016 | 0.29x | CN¥252.69 Million | CN¥864.23 Million | ▲ +37.3% |
| 2015 | 0.21x | CN¥144.69 Million | CN¥679.39 Million | ▼ -32.6% |
| 2014 | 0.32x | CN¥210.49 Million | CN¥666.12 Million | ▲ +44.2% |
| 2013 | 0.22x | CN¥111.03 Million | CN¥506.65 Million | ▲ +92.1% |
| 2012 | 0.11x | CN¥60.28 Million | CN¥528.40 Million | ▼ -29.9% |
| 2011 | 0.16x | CN¥69.41 Million | CN¥426.39 Million | ▲ +72.0% |
| 2010 | 0.09x | CN¥59.55 Million | CN¥629.02 Million | ▼ -57.3% |
| 2009 | 0.22x | CN¥135.38 Million | CN¥610.06 Million | ▲ +381.0% |
| 2008 | 0.05x | CN¥29.98 Million | CN¥649.89 Million | ▲ +137.7% |
| 2007 | -0.12x | CN¥-87.60 Million | CN¥716.18 Million | ▼ -3945.1% |
| 2006 | 0.00x | CN¥-1.45 Million | CN¥478.23 Million | ▼ -101.4% |
| 2005 | 0.22x | CN¥61.82 Million | CN¥279.27 Million | ▲ +523.5% |
| 2004 | 0.04x | CN¥6.43 Million | CN¥181.11 Million | ▼ -86.9% |
| 2003 | 0.27x | CN¥46.18 Million | CN¥170.36 Million | ▼ -28.9% |
| 2002 | 0.38x | CN¥45.50 Million | CN¥119.35 Million | — |